Physician profile
Christopher Pluskota
NPI 1114304029
$3,577.51
in general payments reported to CMS, 2019-2025
22 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what 96% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $12.54 · 2021: $44.11 · 2022: $785 · 2023: $373 · 2024: $706 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,534.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,132.07 | 2019-2025 | |
| Braintree Laboratories, INC. | $476.08 | 2022-2025 | Sutab, Suflave |
| Janssen Biotech, INC. | $297.57 | 2021-2025 | Tremfya, Stelara, Remicade |
| Boston Scientific Corporation | $188.61 | 2020-2025 | Resolution 360 Ultra Clip |
| Pfizer INC. | $138.88 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $132.46 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $128.44 | 2022-2024 | Entyvio |
| Celgene Corporation | $125.00 | 2022 | |
| Lilly USA, LLC | $122.00 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $112.63 | 2022-2023 | Dificid, Zinplava |
| Qol Medical, LLC | $109.20 | 2022-2024 | Sucraid, Sucraid |
| Genzyme Corporation | $108.20 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.46 | 2023-2025 | Xifaxan |
| Shire North American Group INC | $103.40 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $68.81 | 2022-2024 | Dupixent |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $40.92 | 2024-2025 | Vegzelma |
| Covidien LP | $40.90 | 2019 | |
| Ironwood Pharmaceuticals, INC | $40.89 | 2023-2024 | Linzess |
| Ardelyx, INC. | $36.58 | 2024-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $35.40 | 2025 | Rebyota |
| Madrigal Pharmaceuticals | $21.45 | 2025 | Rezdiffra |
| Organon LLC | $11.56 | 2025 | Hadlima, Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Pluskota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.